State medical cannabis laws not associated with reduced use of opioid or nonopioid pain treatments

Embargoed News from Annals of Internal Medicine

2023-07-03

(Press-News.org) 1. State medical cannabis laws not associated with reduced use of opioid or nonopioid pain treatments
Abstract: https://www.acpjournals.org/doi/10.7326/M23-0053
URL goes live when the embargo lifts
A study of commercially insured adults with chronic noncancer pain found that state medical cannabis laws did not affect receipt of opioid or nonopioid pain treatment. These findings suggest that cannabis use has not led to large shifts in pain treatment patterns at the population level. The study is published in Annals of Internal Medicine.

In the 37 states and the District of Columbia (D.C.) with medical cannabis laws, people with chronic noncancer pain are eligible to use cannabis for pain management. The concern is that state medical cannabis laws may lead patients with chronic noncancer pain to substitute cannabis in place of prescription opioid or recommended nonopioid prescription pain medications or procedures. However, the research is not clear.

Researchers from Weill Cornell Medicine studied insurance claims data from 12 states that implemented medical cannabis laws and 17 comparison states to assess the effects of such laws on receipt of prescription opioids, nonopioid prescription pain medications, and procedures for chronic noncancer pain. The researchers found that in any given month during the 3 years of law implementation, medical cannabis laws led to a negligible difference in the proportion of patients receiving any pain medication or chronic pain procedure. According to the researchers, slow implementation could contribute to the study findings. Results also may be explained by reluctance among health system leaders and individual clinicians to recommend cannabis for pain.

Media contacts: For an embargoed PDF, please contact Angela Collom at acollom@acponline.org. To speak with the corresponding author, Emma E. McGinty, PhD, please email Christine Zhuang at chz4003@med.cornell.edu.
--------------------------------
2. Repeat testing with a rapid antigen test may be required to rule out SARS-CoV-2 infection
Abstract: https://www.acpjournals.org/doi/10.7326/M23-0385
URL goes live when the embargo lifts
A prospective cohort study found that repeat testing in 48-hour intervals with a rapid antigen test (Ag-RDT) may be required to rule out SARS-CoV-2 infection. This means that people testing for SARS-CoV-2 should exercise caution in public settings despite an initial negative result if they suspect they may be infected or have been exposed. The findings are published in Annals of Internal Medicine.

Diagnostic testing for SARS-CoV-2 is an important component in the fight against COVID-19, with at-home rapid tests providing a convenient way for people to test. However, the performance of Ag-RDTs for screening asymptomatic and symptomatic persons for SARSCoV-2 is not well established.

Researchers from the University of Massachusetts Chan Medical School studied 5,353 participants who were asymptomatic and negative for SARS-CoV-2 study day 1 to evaluate the performance of Ag-RDTs. Ag-RDTs were collected at home and reverse transcriptase polymerase chain reaction (RT-PCR) tests were shipped to a central laboratory for analysis. The sensitivity of Ag-RDTs was measured on the basis of testing once (same-day), twice (after 48 hours), and thrice (after 96 hours). Using the PCR test as a comparison, the data showed that the performance of the rapid test was optimized when asymptomatic participants tested 3 times at 48-hour intervals and when symptomatic participants tested 2 times at the same interval. False-positive rates were low for rapid tests, suggesting that repeat testing is not needed for those obtaining a positive result on the first or second try. While testing, people should continue to practice mask wearing and social distancing until infection is ruled out.

Media contacts: For an embargoed PDF, please contact Angela Collom at acollom@acponline.org. To speak with the corresponding author Apurv Soni, MD, PhD, please email Sarah Willey at Sarah.Willey@umassmed.edu.
--------------------------------
3. Long-acting injectable ART achieves virologic suppression in patients with detectable viral loads and adherence challenges
Abstract: https://www.acpjournals.org/doi/10.7326/M23-0788
Editorial: https://www.acpjournals.org/doi/10.7326/M23-1427
URL goes live when the embargo lifts
A study of publicly insured adults living with HIV found that long-acting injectable antiretroviral therapy (LA-ART) with cabotegravir (CAB) and rilpivirine (RPV) achieved virologic suppression among most people with detectable viral loads and adherence challenges. The study is published in Annals of Internal Medicine.

Efforts to ensure equitable implementation of LA-ART for people with HIV with viral suppression are needed. Injectable CAB and RPV holds promise for improving outcomes among populations with barriers to adherence, but it is only approved for those who have achieved virologic suppression with use of oral ART before initiating injectables.

Researchers from San Francisco General Hospital sought to examine the effect of LA-ART in publicly insured adults living with HIV who either had viral suppression and wished to switch to LA-ART, or people with HIV and viremia who struggled with daily pill adherence but expressed willingness to visit the clinic for regular injections. The cohort faced barriers to adherence, including high rates of unstable housing, mental illness, and substance use. Among 133 patients in the study, 76 started LA-ART with virologic suppression and 57 started with viremia. All but 2 participants with viremia achieved viral suppression at 26 weeks, which is similar to rates from clinical trials.

According to the authors of an accompanying editorial from Boston Medical Center, these findings provide compelling evidence that LA-ART could change the landscape of HIV treatment and prevention by effectively achieving virologic suppression for patients with viremia where there is the greatest need and opportunity.

Media contacts: For an embargoed PDF, please contact Angela Collom at acollom@acponline.org. To speak with the corresponding author Monica Gandhi, MD, MPH, please contact monica.gandhi@ucsf.edu.
--------------------------------
4. Gender-affirming care provided to cisgender patients highlights unjust bias against transgender patients
Abstract: https://www.acpjournals.org/doi/10.7326/M23-0704
URL goes live when the embargo lifts
Gender-affirming care, such as testosterone therapy and chest surgery, is routinely provided to cisgender patients while legislation in more than 15 states aims to curtail clinician’s authority to provide the same interventions to transgender and gender-diverse (TGD) patients. According to the authors of a commentary published in Annals of Internal Medicine, these gender-affirming procedures are endorsed by every major medical association as standard of care and should be available to all patients without discrimination.

The authors from the Institute for Bioethics and Health Humanities, University of Texas Medical Branch, Galveston demonstrate their point with testosterone therapy and chest surgery because both procedures hold gender affirmation as a goal and share the qualities of being initiated by the patient and evaluated on psychosocial outcomes. Systematic reviews of gender-affirming hormone therapy and surgery for TGD patients report improvements in psychosocial outcomes in many of the same metrics used to evaluate outcomes in cisgender gender-affirming care, including low rates of complications and psychosocial benefits. A look at these procedures shows how current medical practice already provides gender-affirming care for many cisgender patients. Considering how they have been treated differently in practice and policy reveals discrimination being made between categories of people, the authors note.

Media contacts: For an embargoed PDF, please contact Angela Collom at acollom@acponline.org. To speak with the corresponding author Jacob D. Moses, PhD, please contact Christopher Smith Gonzalez at chrissmi@UTMB.EDU.
--------------------------------

END

ELSE PRESS RELEASES FROM THIS DATE:

NASA’s Parker Solar Probe completes 16th close approach to the Sun

2023-07-03

NASA’s Parker Solar Probe accomplished a milestone on June 27, 2023 – its 16th orbit of the Sun. This included a close approach to the Sun (known as perihelion) on June 22, 2023, where the spacecraft came within 5.3 million miles of the solar surface while moving at 364,610 miles per hour. The spacecraft emerged from the solar flyby healthy and operating normally. On Aug. 21, 2023, Parker Solar Probe will swing past Venus for its sixth flyby of the planet. To prepare for a smooth course, the mission team at the Johns Hopkins Applied Physics ...

Researchers identify a new mechanism, cancer hijacks enzyme substrate motif mutations

2023-07-03

CHAPEL HILL, N.C. – Cancer spreads throughout the human body in cunning, almost militaristic, ways. For example, it can manipulate our genetic make-up, take over specific cell-to-cell signaling processes, and mutate key enzymes to promote tumor growth, resist therapies, and hasten its spread from the original site to the bloodstream or other organs. Enzyme mutations have been of great interest to scientists who study cancer. Scientists in the Liu and Tan labs at UNC’s Lineberger Comprehensive Cancer Center have been studying mutations of enzyme recognition motifs in substrates, ...

Researchers develop tool that could improve liquid biopsy

2023-07-03

A research team led by Xianghong Jasmine Zhou, PhD, professor of Pathology and Laboratory Medicine at the David Geffen School of Medicine at UCLA, has made an important advancement to address one of the major challenges in cell-free DNA (cfDNA) testing, also known as liquid biopsy. They’ve identified specific methylation patterns unique to each tissue, potentially helping to Identify the specific tissue or organ associated with cfDNA alterations picked up by testing, a critical challenge for accurate diagnosis and monitoring of diseases. Cell-free DNA has significant potential in disease detection and monitoring. However, accurately quantifying tissue-derived ...

Cigarette smoke and HPV have synergistic effects on cells, heightening the risk of head and neck cancer

2023-07-03

Tobacco smoking and human papillomavirus (HPV) are both well-known risk factors for head and neck cancer, but there is ample evidence to show they can interact to increase still further the risk of contracting the disease, according to a study by scientists at the University of São Paulo (USP) in Brazil and the University of Chile. An article on the study is published in the International Journal of Molecular Sciences. The results of the study clarify aspects of the molecular mechanisms ...

ERβ as a mediator of estrogen signaling in inflammatory breast cancer

2023-07-03

“The mechanism of the anti-metastatic activity of ERβ was investigated [...]” BUFFALO, NY- July 3, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, “ERβ as a mediator of estrogen signaling in inflammatory breast cancer.” In this new editorial, researchers Harika Nagandla and Christoforos Thomas from Houston Methodist Neal Cancer Center discuss inflammatory breast cancer (IBC)—a rare and aggressive form of breast ...

Pathogenic bacteria use a sugar in the intestinal mucus layer to infect the gut, study shows

2023-07-03

A new study by researchers at the University of British Columbia (UBC) and BC Children’s Hospital shows the sugar sialic acid, which makes up part of the protective intestinal mucus layer, fuels disease-causing bacteria in the gut. The findings, published in PNAS, suggest a potential treatment target for intestinal bacterial infections and a range of chronic diseases linked to gut bacteria, including inflammatory bowel disease (IBD), celiac disease, irritable bowel syndrome and short bowel syndrome. “Bacteria need to find a place in our intestines to take hold, establish and expand, and then they need to overcome all the different defences that normally protect our ...

Birds raise fewer young when spring arrives earlier in a warming world

2023-07-03

Rising global temperatures are making it harder for birds to know when it’s spring and time to breed according to a new study published in Proceedings of the National Academy of Sciences. A large collaboration led by scientists at UCLA and Michigan State University has found that birds produce fewer young if they start breeding too early or late in the season. With climate change resulting in earlier springlike weather, the researchers report, birds have been unable to keep pace. And, the authors write, the mismatch between the ...

Chemists discover why photosynthetic light-harvesting is so efficient

2023-07-03

When photosynthetic cells absorb light from the sun, packets of energy called photons leap between a series of light-harvesting proteins until they reach the photosynthetic reaction center. There, cells convert the energy into electrons, which eventually power the production of sugar molecules. This transfer of energy through the light-harvesting complex occurs with extremely high efficiency: Nearly every photon of light absorbed generates an electron, a phenomenon known as near-unity quantum efficiency. A new study from MIT chemists offers a potential explanation for how proteins of the light-harvesting complex, also called the antenna, achieve that ...

Planting seeds: FSU researchers dig into how chemical gardens grow

2023-07-03

EMBARGOED UNTIL JULY 3 AT 3 P.M. ET FOR IMMEDIATE RELEASE CONTACT: Kathleen Haughney, University Communications (850) 644-1489; khaughney@fsu.edu July 2023 PLANTING SEEDS: FSU RESEARCHERS DIG INTO HOW CHEMICAL GARDENS GROW TALLAHASSEE, Fla. — Since the mid-1600s, chemists have been fascinated with brightly colored, coral-like structures that form by mixing metal salts in a small bottle. Until now, researchers have been unable to model how these deceptively simple tubular structures —called chemical gardens — work and the patterns and rules that ...

Understanding the regulation of apicoplast gene expression in the malaria parasite

2023-07-03

Gene expression within the apicoplast, an organelle in the malaria parasite Plasmodium falciparum, is regulated by melatonin (the circadian signaling hormone) in host blood, and intrinsic parasite cues, via a factor called ApSigma, as identified by a recent study aided by Tokyo Tech’s World Research Hub Initiative. The regulatory system highlighted in this study might be a future target for malaria treatment. Malaria is one of the biggest public health risks, with around 240 million people from across the globe contracting it every year. However, this life-threatening disease is ...

State medical cannabis laws not associated with reduced use of opioid or nonopioid pain treatments

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: